Transgene SA announces late-stage development of the first-line treatment of liver cancer

Transgene SA (NYSE-Euronext: TNG), Lee’s Pharmaceuticals (HKEx: 0950) and SillaJen announced plan of late-stage development for Pexa-Vec (JX-594/TG6006). The companies plan to  initiate a global Phase 3 study in the first-line treatment of advanced hepatocellular carcinoma patients and some Phase 1/2 trials in different cancers as a single agent or in combination with other medicines. According with Phase 2 study, Pexa-Vec has demonstrated high efficacy and was associated with longer survival benefit in first-linge therapy of liver cancer. Schaduled Phase 3 trial will access use of Pexa-Vec with following treatment with sorafenib. The randomized multi-centered study will be conducted in Europe, Asia and America and is expected to start recruitment by the mid-2015.

Last year company announced successful finishing  of Phase 2 trial of vaccinia-based gene therapy  TG4004 in chronic hepatitis C patients.